The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two new rescue therapies for “off” periods are or soon will be available (i.e., Inbrija, APL-130277); and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Gocovri, Nuplazid) or are in late-phase development (e.g., P2B001, TD-9855). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales of PD therapies. However, given the cost-sensitivity of PD patients and the widespread availability of generic and—for many patients—therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.

Questions Answered:

  • What will be the impact of forthcoming levodopa reformulations? Will they alter the PD treatment paradigm or be sidelined by access hurdles and/or physician resistance?
  • What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in PD?
  • How do neurologists differentiate among levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which of these therapies will enjoy the greatest clinical and commercial success in this highly generic market?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 32 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase II: 24 drugs; Phase III: 6 drugs; preregistration: 1 drug.

Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2028, segmented by brands/generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Eisai, Hisamitsu Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, Theravance Biopharma, UCB, US WorldMeds, Zambon Pharma.

Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951, AP-CD/LDAPL-130277, Duodopa/Duopa, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, Trerief, Xadago.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Parkinson's Disease - Key Findings - May 2020
    • Key Updates
      • May 2020
      • December 2019
      • August 2019
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Parkinson's Disease?
        • What Factors Are Constraining the Market for Parkinson's Disease?
      • Drug-Class-Specific Trends
        • Dopamine Precursors
        • Dopamine Agonists
        • MAO-B Inhibitors
        • COMT Inhibitors
        • Adenosine A2A Receptor Antagonists
        • Antiglutamatergic Agents
        • Acute Rescue Therapies
        • Antipsychotic Agents
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
      • Disease Progression
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Parkinson's Disease
        • Diagnosed Prevalent Cases of Parkinson's Disease
        • Drug-Treated Prevalent Cases of Parkinson's Disease
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Dopamine Precursors
        • Dopamine Agonists
        • MAO-B Inhibitors
        • COMT Inhibitors
        • Adenosine A2A Receptor Antagonists
        • Antiglutamatergic Agents
        • Acute Rescue Therapies
        • Antidementia Agents
        • Antipsychotic Agents
        • Other Agents
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Parkinson's Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Dopamine Precursors
        • Dopamine Agonists
        • Acute Rescue Therapies
        • Agents for Nonmotor Symptoms in PD
      • Early-Phase Pipeline Analysis
        • Challenges to Developing Disease-Modifying Therapies for Parkinson's Disease
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Parkinson's Disease Bibliography

Author(s): Bethany Christmann, PhD; Abey John, MPH

Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Parkinson's Disease | Unmet Need | Detailed, Expanded Analysis: Psychosis in PD (US/FR/DEU/UK)

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD pat...

View Details

Parkinson's Disease | Disease Landscape and Forecast | G7 | 2019

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two new re...

View Details

Parkinson's Disease | Access & Reimbursement | Detailed, Expanded Analysis (US)

Since 2015, several new brands have launched in the United States for the treatment of motor and nonmotor symptoms in Parkinson’s disease (PD), and yet more are on the near-term horizon. Ch...

View Details

Parkinson's Disease | Epidemiology | Americas

DRG Epidemiology's coverage of Parkinson's disease (PD) comprises epidemiological estimates of key p...

View Details